Kimberly-Clark names new director of global marketing
IRVING, Texas Mark Kaline has been named to the Kimberly-Clark management team to serve in a new position—global media director, the company said Tuesday. Kaline officially takes his chair Oct. 20.
The Global Marketing Organization at Kimberly-Clark, which was formed last April, directs attention towards global brand-building and instituting and perpetuating best practices in its business divisions, the company said.
Kaline joins Kimberly-Clark’s global marketing team after working for Ford Motor Company as online and traditional media buying manager for about 11 years. He also worked for Ford’s consolidated media operations in Canada, Europe and Mexico and created the Branded Entertainment Group at Ford.
Campaign for Tobacco-Free Kids targets R.J. Reynolds marketing of smoke-free products
WASHINGTON Plans by R.J. Reynolds to test market three new smokeless tobacco products have drawn ire from the Campaign for Tobacco-Free Kids.
The three products, marketed under the Camel brand as Camel Strips, Sticks and Orbs, dissolve in the mouth and come in “fresh” and “mellow” flavors, RJR has advertised. RJR is testing them in Indianapolis, Columbus, Ohio, and Portland, Ore.
“RJR’s new products add to a growing list of novel products tobacco companies have introduced recently in their relentless efforts to recruit new youth users, create and sustain addiction to nicotine and discourage current users from quitting,” the campaign said in a statement. “The tobacco industry will continue to get away with these harmful practices until Congress ends the industry’s regulatory exemption and passes legislation granting the [Food and Drug Administration] authority over tobacco products.”
Specialists testify that Pfizer tampered with study results for epilepsy drug
NEW YORK Experts reviewing documents in a lawsuit against Pfizer said in federal court in Boston Monday that the company manipulated the publication of studies to influence sales of the epilepsy drug Neurontin (gabapentin).
The experts said Pfizer delayed publication of studies that cast doubt on the drug’s efficacy and used spin tactics to downplay negative data.
In a statement Tuesday, Pfizer denied manipulating the data, maintaining that the study results were objective, accurate, balanced and complete.